Abstract:Objective To evaluate the effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in the short-course supplementary treatment of acute leukemia on the inhibitory period of bone marrow induced by intense chemotherapy. Methods Forty-five cases of acute leukemia were divided randomly into two groups.Routine treatment was conducted in the routine group , while the patients in the supplementary therapy group received rhG-CSF on the first three days as a supplementary therapy besides routine treatment. Results The inhibitory period of bone marrow and controlled period of infection were significantly shortened in the supplementary therapy group than in the routine group. The required volume of blood transfusion was significantly smaller in the supplementary therapy group (340 ml) than in Group R (540 ml). There was no significant difference between the two groups in the secondary infection occurrence rate, remission rate, and disease-free survival. Conclusions The short-course administration of rhG-CSF as a supplementary therapy seems to reduce the inhibition of bone marrow induced by intense chemotherapy in acute leukemia and thus may be helpful to accomplish the intense chemotherapy. Due to the beneficial effects and low costs of rhG-CSF, it may be worthwhile to popularize its application as a supplementary therapy in acute leukemia.
